JPMorgan analyst Brian Ossenbeck lowered the firm’s price target on RXO Inc. (RXO) to $14 from $15 and keeps an Underweight rating on the shares. The firm says the company’s “weak” Q4 results and lower than expected guidance confirmed its concerns that RXO would be unable to offset elevated buy rates with incremental spot opportunities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO Inc. price target raised to $17 from $16 at BofA
- RXO Inc. price target raised to $17 from $15 at UBS
- Balanced Hold on RXO: Near-Term Earnings Pressure vs. Emerging Truckload Recovery Upside
- Balancing Near-Term Weakness and AI-Driven Upside: Why RXO Merits a Buy Rating
- RXO Establishes New Credit Facility Amid Weaker Earnings